JP2017176174A5 - - Google Patents

Download PDF

Info

Publication number
JP2017176174A5
JP2017176174A5 JP2017057024A JP2017057024A JP2017176174A5 JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5 JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
region
same amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017057024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017176174A (ja
JP6392923B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017176174A publication Critical patent/JP2017176174A/ja
Publication of JP2017176174A5 publication Critical patent/JP2017176174A5/ja
Application granted granted Critical
Publication of JP6392923B2 publication Critical patent/JP6392923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017057024A 2008-10-06 2017-03-23 Ｍｕｃ１＊抗体 Active JP6392923B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10320408P 2008-10-06 2008-10-06
US61/103,204 2008-10-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014226709A Division JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体

Publications (3)

Publication Number Publication Date
JP2017176174A JP2017176174A (ja) 2017-10-05
JP2017176174A5 true JP2017176174A5 (https=) 2017-11-16
JP6392923B2 JP6392923B2 (ja) 2018-09-19

Family

ID=42101177

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011531128A Pending JP2012504961A (ja) 2008-10-06 2009-10-06 Ｍｕｃ１＊抗体
JP2014226709A Active JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体
JP2017057024A Active JP6392923B2 (ja) 2008-10-06 2017-03-23 Ｍｕｃ１＊抗体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011531128A Pending JP2012504961A (ja) 2008-10-06 2009-10-06 Ｍｕｃ１＊抗体
JP2014226709A Active JP6230983B2 (ja) 2008-10-06 2014-11-07 Ｍｕｃ１＊抗体

Country Status (8)

Country Link
US (4) US20170204191A1 (https=)
EP (3) EP4083072B1 (https=)
JP (3) JP2012504961A (https=)
KR (1) KR101455447B1 (https=)
CN (1) CN102239182B (https=)
CR (1) CR20110238A (https=)
IL (1) IL212175B (https=)
WO (1) WO2010042562A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170204191A1 (en) 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
WO2010042891A2 (en) * 2008-10-09 2010-04-15 Minerva Biotechnologies Corporation Method for inducing pluripotency in cells
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP3228629A1 (en) * 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
CN102716472A (zh) * 2011-03-31 2012-10-10 李光辉 一种肿瘤疫苗及其合成方法
JP6748430B2 (ja) * 2012-07-13 2020-09-02 ミネルバ バイオテクノロジーズ コーポレーション より未分化状態への細胞の誘導方法
CN104717980A (zh) * 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
CA2886161A1 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
US9988442B2 (en) 2013-01-23 2018-06-05 Syddansk Universitet MFAP4 binding antibodies blocking the interaction between MFAP4 and integrin receptors
US10059775B2 (en) 2014-01-29 2018-08-28 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
CN106414726A (zh) 2014-04-07 2017-02-15 米纳瓦生物技术公司 抗nme抗体
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US10450376B2 (en) * 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
CN117442748A (zh) 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
US9688750B2 (en) 2014-10-07 2017-06-27 Ann And Robert H. Lurie Children's Hospital Of Chicago Anti-nodal antibodies and methods of using same
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017100670A1 (en) * 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
CN109195992A (zh) * 2016-04-29 2019-01-11 本康生物制药（深圳）有限公司 多特异性结合偶联物、相关的药物组合物及应用
CA3050039A1 (en) * 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
CN118267470A (zh) * 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CN109971713B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
JP7779653B2 (ja) * 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
US20200405832A1 (en) * 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
JP2022527144A (ja) * 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
CN116367857A (zh) 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
KR20230028796A (ko) * 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
US20230265208A1 (en) * 2020-07-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
BR112023001739A2 (pt) 2020-07-31 2023-02-28 Scherer Technologies Llc R P Anticorpo específico para mucina-1 e métodos de uso do mesmo
KR20250009592A (ko) 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도
AU2024206813A1 (en) * 2023-01-04 2025-06-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-muc1 antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025080693A1 (en) 2023-10-11 2025-04-17 Minerva Biotechnologies Corporation Anti-muc1* antibody drug complexes and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020136725A1 (en) 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
TWI242563B (en) 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
EP1131106B1 (en) 1998-11-12 2009-06-24 Novolytics Inc. Compositions and methods for producing vascular occlusion
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2001075110A2 (en) * 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
DE60130891T2 (de) 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
AU9263101A (en) * 2000-09-11 2002-03-26 Donald W Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
EP2322929B1 (en) * 2000-11-27 2016-04-06 Minerva Biotechnologies Corporation diagnostics, drug screening and treatment for cancer
EP1578345A2 (en) 2001-03-29 2005-09-28 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Peptides and antibodies to muc 1 proteins
US7630836B2 (en) 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
US7282567B2 (en) * 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
WO2003089451A2 (en) 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
CA2537263C (en) * 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060173171A1 (en) 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
BRPI0515670A (pt) 2004-10-04 2008-07-29 Genentech Inc anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met
CA2610292C (en) * 2005-03-30 2015-06-02 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
CN101652469B (zh) 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
US8420591B2 (en) * 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
US20170204191A1 (en) 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
CN104717980A (zh) * 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
CA2976089C (en) * 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies

Similar Documents

Publication Publication Date Title
JP2017176174A5 (https=)
JP2018504907A5 (https=)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
JP2019524645A5 (https=)
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
JP2014205674A5 (https=)
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
JP2016185981A5 (https=)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
JP2019528240A5 (https=)
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
CN110291109A (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
JP2013539454A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
AR105267A1 (es) Anticuerpos de unión a tau
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
PE20190737A1 (es) Anticuerpos anti-cd27
JP2018537399A5 (https=)
WO2012047732A3 (en) Antibody compositions and methods of use